We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue

Highly Sensitive Molecular Test Detects Cases of Tuberculosis

By LabMedica International staff writers
Posted on 28 Jun 2021
Print article
Image: Xpert MTB/RIF Ultra assay is an automated molecular test that has improved the detection of tuberculosis and rifampicin resistance (Photo courtesy of Cepheid)
Image: Xpert MTB/RIF Ultra assay is an automated molecular test that has improved the detection of tuberculosis and rifampicin resistance (Photo courtesy of Cepheid)
Tuberculosis (TB) is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. It mainly affects the lungs, but it can affect any part of the body, including the tummy (abdomen), glands, bones and nervous system.

Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Most infections show no symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those affected. Typical symptoms of active TB are a chronic cough with blood-containing mucus, fever, night sweats, and weight loss.

A team of Medical Scientists at the Barcelona Institute for Global Health (Barcelona, Spain) and their colleagues enrolled a total of 1,419 and 252 participants in the passive case finding (PCF) and (active case finding (ACF) cohorts. Single respiratory specimens from symptomatic adults accessing health care services PCF cohort, and from household and community close contacts ACF, were tested by smear microscopy, culture, sensitive molecular tests. Liquid and solid culture served as a composite reference standard. The team performed a field study to compare the performance of two molecular tests: 'Xpert MTB/RIF', developed in 2010, and its improved version, Xpert Ultra (Cepheid, Sunnyvale, CA, USA), developed three years ago and capable of detecting smaller amounts of DNA.

The investigators reported that for the PCF cohort, Ultra showed higher sensitivity than Xpert overall (0.95 (95% CI: 0.90, 0.98) versus 0.88 (0.82, 0.93) and among smear negative patients (0.63 (0.48, 0.76) and 0.84 (0.71, 0.93). Ultra's specificity was lower than Xpert's 0.98 (0.97, 0.99) versus 0.96 (0.95, 0.97). For ACF, sensitivities were the same (0.67 (95% CI: 0.22,0.96) for both tests), although Ultra detected a higher number of microbiologically confirmed samples than Xpert (12/252 (4.7%) versus 7/252 (2.7%). Conditional recategorization of trace results among previously treated participants maintained differences in specificity in the PCF cohort. Among the cohort of case contacts, the incidence was much lower, but even then the Ultra managed to detect cases that were not detected by Xpert or by liquid culture, likely because they had a very low burden of bacteria.

Alberto L. García-Basteiro, MD, PhD, an expert in tuberculosis and senior author of the study, said, “Most national programmes for TB control focus on detecting cases that attend the hospital, which tend to be more severe, but there are many cases with no or few symptoms that we are missing. If we want to achieve the End TB goals, we need to develop new diagnostic tools capable of identifying patients at earlier stages of the disease, with lower bacterial burdens, and that can be deployed at the patient's point of care.” The study was published on June 17, 2021 in the European Respiratory Journal.

Related Links:
Barcelona Institute for Global Health
Cepheid


Gold Supplier
Sample Transport
VACUETTE Transport Line
New
COVID-19 IgG/IgM Antibody Test
Artron COVID-19 IgG/IgM Antibody Test
New
Gold Supplier
SARS-CoV-2 Genome RNA Controls
AMPLIRUN SARS-CoV-2 RNA CONTROL PANEL
New
Molecular Diagnostic System
iPonatic

Print article

Channels

Molecular Diagnostics

view channel
Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)

APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.